Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLoans - Loss AllowanceNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Finished Goods: 2017-2024

  • RedHill Biopharma's Finished Goods fell 14.96% to $2.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was $2.8 million, marking a year-over-year decrease of 14.96%. This contributed to the annual value of $2.8 million for FY2024, which is 14.96% down from last year.
  • According to the latest figures from Q4 2024, RedHill Biopharma's Finished Goods is $2.8 million, which was down 14.96% from $3.3 million recorded in Q4 2023.
  • RedHill Biopharma's 5-year Finished Goods high stood at $6.8 million for Q4 2022, and its period low was $2.8 million during Q4 2024.
  • For the 3-year period, RedHill Biopharma's Finished Goods averaged around $4.3 million, with its median value being $3.3 million (2023).
  • Per our database at Business Quant, RedHill Biopharma's Finished Goods spiked by 1,521.23% in 2020 and then crashed by 51.25% in 2023.
  • RedHill Biopharma's Finished Goods (Quarterly) stood at $4.7 million in 2020, then spiked by 39.48% to $6.6 million in 2021, then increased by 3.39% to $6.8 million in 2022, then crashed by 51.25% to $3.3 million in 2023, then fell by 14.96% to $2.8 million in 2024.
  • Its Finished Goods stands at $2.8 million for Q4 2024, versus $3.3 million for Q4 2023 and $6.8 million for Q4 2022.